Home
Revascularisation for Ischaemic Ventricular Dysfunction
A multicentre prospective randomised open controlled trial.
Aim: To evaluate the efficacy and safety of percutaneous coronary intervention compared to optimal medical therapy alone for ischaemic left ventricular dysfunction.
Primary Endpoint: All-cause death or hospitalisation due to heart failure
Secondary Endpoints:
- Quality of life score:
- Kansas City Cardiomyopathy Questionnaire (KCCQ)
- EuroQol EQ-5D-5L
- NYHA Functional Class
- LVEF on echocardiography at 6 months and 1 year
- Cardiovascular death, MI, CVA, major bleeding or unplanned revascularisation at 30 days
- Hospitalisation for heart failure
- Cardiovascular death
- Acute myocardial infarction
- Appropriate ICD therapy
- Unplanned further revascularisation
- Canadian Cardiovascular Society (CCS) class
- NHS resource use
- Brain natriuretic peptide (BNP or NT-Pro BNP) level
- Major bleeding